Mr. Sharad Vadehra

Country/Region of practice
India
Pronouns:
He/him/his
About me

Sharad Vadehra is the Managing Partner at KAN AND KRISHME. He joined the profession in the year 1989, and is amongst the few Attorneys in the country with both technical and legal qualifications.

 

 

 

 

 

 

 

Sharad specializes in Intellectual Property Laws, Media, Entertainment, Sweepstake and Promotions, Marketing, Commercial disputes and Litigation and has more than 26 years’ experience in these fields and in handling such matters for both domestic and international companies (including fortune 500 companies) and

research institutions. Sharad has prosecuted, defended, opposed/or enforced directly or in supervisory capacity over 25,000 patent matters in India and abroad. He has been a speaker in over five hundred institutions and corporate bodies in India and overseas, and is the author of the book “Indian Patent Law and Practice” published by Chosakai in Japan in Japanese language.

 

 

 

 

 

 

 

 

 

Sharad has often been consulted by the Government of India when any new guidelines or rules are being framed with respect to the Indian Patent Act and Rules.

 

 

 

 

 

 

 

 

 

 

 

Experience & Qualifications

Technical Specialisms
  • Biochemistry and pharmacology
  • Chemistry
  • Physics
Professional Experience
  • Patent drafting
  • Patent oppositions
  • Patent prosecution
  • Trade mark oppositions
  • Trade mark prosecution

Roles in FICPI

  • CET 5 Biotechnology and Pharmaceuticals

    CET Group 5 is dedicated to following, reporting and providing substantive comments and opinions on emerging issues relating to the patenting and regulatory affairs in the Biotechnology and Pharmaceutical fields. 

    In addition, CET 5 is closely following developments related to genetic resources and developing requirements for notice on their country of origin.  Prominent issues CET 5 addresses regarding patenting in these technological fields include subject matter eligibility, and in particular, the patentability of chemical/biological inventions developed using machines, computer implementation and/or artificial intelligence.  CET 5 supports FICPI in its mission to be an international leader promoting patent protection in the biotechnology and pharmaceutical arts.

  • Member